Avatar for Verge Genomics

Next-generation medicines unlocked from and tailored to individual humans

Next-generation medicines unlocked from and tailored to individual humans

Verge Genomics is a next-generation drug discovery company that is using human genomic data to defeat neurodegeneration. In just the last year, we have built the field's largest human brain genomic database, closed two pharma partnerships, and made important breakthroughs on two novel therapeutic targets in ALS patient neurons.

Founded by scientists from leading neuro-genomics labs, the Verge team is 14 people including 12 Ph.D.s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, and UCSF, two former professors, and two pharma veterans who have taken drugs from idea to clinic (including a leading schizophrenia drug in market and a non-addictive pain opiate).
image

Future Opportunities

Apply now

Latest Stories and News

Machine learning company Insitro raises $143 million to bridge biology and AI

  • Forbes
  • this week
  • The San Francisco-based company, with a goal of meshing data science and life science, announced Tuesday that it’s raised a $143 million round of funding, bringing the total amount of venture capital its raised to $243 million.
  • Andreessen led the funding round, which included new investors T. Rowe Price Associate, BlackRock, Casdin Capital and CPP Investments. Current investors including ARCH Venture Partners, GV and Third Rock Ventures also participated.
  • Some of the new capital from the funding round will go towards building up the company’s capabilities to develop drugs, including eventually hiring regulatory experts and other staff that have experience with drug development.
 Machine learning company Insitro raises $143 million to bridge biology and AI
Total raised

$36M

Funded over

2 rounds

Latest round

Series A (Jul 2018)

401k

Foods

Gym

Activities

Parking

+1 more